Clinical Trial: Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07764978) titled 'Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT' on July 01.

Brief Summary: This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.

Study Start Date: June 26

Study Type: INTERVENTIONAL

Condition: Newly Diagnosed Multiple Myeloma

Intervention: BIOLOGICAL: A...